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Abstract
Background: Disease incidence data are needed to guide decision-making for public health interventions. Although dengue
is a reportable disease in Thailand and Cambodia, the degree that reported incidence underrecognizes true disease burden
is unknown. We utilized dengue incidence calculated from laboratory-confirmed outpatient and inpatient cases in
prospective cohort studies to estimate the magnitude of dengue underrecognition and to establish more accurate disease
burden estimates for these countries.
Methods and Findings: Cohort studies were conducted among children aged ,15 years by members of a dengue field site
consortium over at least 2 dengue seasons. Age-group specific multiplication factors (MFs) were computed by comparing
data from three cohort studies to national surveillance data in the same province and year. In Thailand, 14,627 person-years
of prospective cohort data were obtained in two provinces and 14,493 person-years from one province in Cambodia.
Average annual incidence of laboratory-confirmed dengue was 23/1,000 and 25/1,000 in Thailand, and 41/1,000 in
Cambodia. Calculated MFs in these provinces varied by age-group and year (range 0.4–29). Average age-group specific MFs
were then applied to country-level reporting data and indicated that in Thailand a median 229,886 (range 210,612–331,236)
dengue cases occurred annually during 2003–2007 and a median 111,178 (range 80,452–357,135) cases occurred in
Cambodia in children ,15 years of age. Average underrecognition of total and inpatient dengue cases was 8.7 and 2.6-fold
in Thailand, and 9.1 and 1.4-fold in Cambodia, respectively. During the high-incidence year 2007, .95,000 children in
Thailand and .58,000 children in Cambodia were estimated to be hospitalized due to dengue.
Conclusion: Calculating MFs by comparing prospective cohort study data to locally-reported national surveillance data is
one approach to more accurately assess disease burden. These data indicate that although dengue is regularly reported in
many countries, national surveillance data significantly underrecognize the true burden of disease.
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Introduction
Dengue is a mosquito-borne viral disease that is increasing in
incidence and economic importance [1]. It is endemic in most
tropical areas of Asia, the Americas, and some parts of Sub-
Saharan Africa [1]. Most dengue virus (DENV) infections occur
either asymptomatically or present clinically as undifferentiated
fever, followed, in increasing rarity, by classic dengue fever (DF)
and dengue hemorrhagic fever (DHF) [2].
Evidence of the magnitude and trends of diseases should
contribute to decision-making at the global and national levels,
especially in the context of increasing health care costs and
increasing availability of effective interventions [3]. For dengue, it
is estimated that about 50–100 million individuals are infected
annually worldwide with up to 500,000 people being admitted to
hospital [4]. However, it is generally believed that these numbers
still represent a large underestimate of the actual disease burden.
In most countries, reporting of dengue is based solely on clinical
criteria. The variable clinical picture of dengue, and the diagnostic
confusion with other similarly presenting febrile diseases, compli-
cates dengue disease surveillance [5]. In addition, in some
countries only hospitalized dengue cases are reported to national
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objective of these systems is to detect epidemics, guide immediate
actions, and monitor trends [5].
Due to the underrecognition of cases, data drawn from national
or regional surveillance and reporting systems are usually not
sufficient to be used for disease or economic burden estimates. To
overcome this problem, authors of several published dengue
studies multiplied the number of reported cases by a set factor to
obtain an estimate of actual cases [6–8]. Usually these multipli-
cation factors (MFs) have been based on data derived from a single
study, often performed in a different country, or based on ‘‘expert
opinion’’ [6,7]. For example, the authors of a study that assessed
the disability adjusted life years lost to dengue in Brazil used a
range of MFs (from 0.3 through 10) with the upper limit estimate
derived from a cohort study in Thailand, given the uncertainties
regarding the magnitude of disease underrecognition in their
country [8]. Attempts to systematically assess such MFs, for
example through capture-recapture studies, have only rarely been
undertaken and usually have not taken outpatients into account
[9]. But a recent study from Thailand clearly demonstrated that
non-hospitalized patients with dengue illness represent a substan-
tial proportion of the overall disease burden [10].
Over the past 30 years dengue has been a major public health
problem in Thailand and Cambodia, where children below 15
years of age are especially affected [11,12]. In both countries DF
and DHF cases are notifiable. In Thailand, dengue case
surveillance is mainly based on clinical and general laboratory
criteria, and there is an emphasis on hospitalized cases in spite of
encouragement for outpatient reports [12]. In Cambodia, only
hospitalized children ,15 years of age are reportable to the
Ministry of Health (MoH).
The Pediatric Dengue Vaccine Initiative (PDVI), a product
development partnership of the International Vaccine Institute
(IVI) in Seoul, Korea, whose goal is to accelerate the development,
evaluation and introduction of dengue vaccines, has established a
field site consortium, which includes three member field sites from
Thailand and Cambodia, each having conducted at least two years
of active dengue surveillance within defined cohorts as of 2008.
The objective of this study was to utilize laboratory-confirmed
incidence of symptomatic DENV infection both in inpatients and
outpatients identified in prospective cohort studies at these three
field sites to estimate the magnitude of dengue underrecognition in
Thailand and Cambodia. Accurate country-specific incidence data
are crucial for the assessment of the economic impact of dengue
and the cost-effectiveness of a potential dengue vaccine in the
future.
Methods
To estimate the true number of dengue cases in Thailand and
Cambodia, we compared field site data with reported data on the
provincial level in order to establish age-group specific MFs.
Prospective cohort data were used from three provinces:
Kamphaeng Phet and Ratchaburi in Thailand, and Kampong
Cham in Cambodia.
The two cohort studies in Thailand
Prospective data from two cohort studies in Thailand were
included in the analysis. Demographics for these two sites are
based on population census data as of 2000 [13]. One study has
been conducted since 1998 in Muang district of Kamphaeng Phet
Province, located 350 km northwest of Bangkok (Figure 1). By
Thai standards, the study area is relatively sparsely populated with
206,271 residents in 56,874 households in an area encompassing
1,384 km
2 (population density: 149/km
2). Approximately 30% of
the total provincial population lives in Muang district (province
population density: 78/km
2). Further details of this study sites and
the cohort study designs have been published previously [14]. The
other cohort study has been carried out since 2005 in Muang
district of Ratchaburi Province, which is located 100 km west of
Bangkok at the Thai-Myanmar border (Figure 1). A total 183,528
residents live in 47,608 households in the urban Muang district
(area of 418 km
2, population density: 439/km
2). Approximately
23% of the total provincial population lives in Muang district
(province population density: 161/km
2). To compare the cohort
data with provincial reporting data, we included in the analysis
data gathered within the Kamphaeng Phet cohort between 2004
and 2007 (in 2003 no dengue surveillance was conducted within
this cohort) and within the Ratchaburi cohort between 2006 and
2007.
In Kamphaeng Phet, approximately 2,000 children from
kindergarten to grade five (age-range: 4 to 13 years of age) at 11
local primary schools were recruited into a dynamic cohort in
January 2004. New participants were enrolled from the kinder-
garten class in January of each year to replace subjects who
graduated from the sixth grade. In Ratchaburi, the cohort was
fully established in February 2006 including 3,026 students aged
3–14 years attending 7 local schools. Children who left the cohort
in 2006 were replaced in February of the following year with
students in the same age-range. For both cohort studies, sample
size calculations based on expected dengue incidences in the target
population.
In both cohorts, acute dengue illness was identified on the basis
of absence from school or a visit to the school nurse or the involved
health centers (Kamphaeng Phet) and regional hospital (Ratch-
aburi). While active case surveillance of study participants for
acute illness occurred in Ratchburi throughout the whole year,
surveillance in Kamphaeng Phet was limited to the dengue season
from June to November each year.
In both studies, acute-illness and convalescent (i.e. 10–21 days
later) blood samples were obtained from all students with a history
of fever within the previous 7 days or an oral temperature of
$38uC after obtaining signed parental consent. In Ratchaburi,
however, in the first year blood was only collected from students
with clinically suspected dengue (i.e. fever for .2 days and no
localizing signs, or any child fulfilling the WHO dengue clinical
Author Summary
Dengue is a major public health problem especially in
tropical and subtropical countries of Asia and Latin-
America. An effective dengue vaccine is not yet available,
but several vaccine candidates are currently being
evaluated in clinical trials. Accurate country-level incidence
data are crucial to assess the cost-effectiveness of such
vaccines and will assist policy-makers in making vaccine
introduction decisions. Existing national surveillance sys-
tems are often passive and are designed to monitor trends
and to detect disease outbreaks. Our analyses of data from
prospectively followed cohorts with laboratory confirma-
tion of dengue cases show that, in Thailand and Cambodia,
dengue incidence is underrecognized by more than 8-fold.
The magnitude of the outpatient burden caused by
dengue is not assessed or reflected by the national
surveillance data. We estimate that a median of more
than 340,000 symptomatic dengue virus infections oc-
curred annually in children less than 15 years of age in
Thailand in Cambodia between 2003 and 2007.
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field site consortium and provided prospective cohort data to be compared with the dengue reporting data in the same province.
doi:10.1371/journal.pntd.0000996.g001
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Kamphaeng Phet study by using the AFRIMS in-house dengue
IgM/IgG enzyme immunoassay (EIA) in acute and convalescent
sera, or reverse-transcriptase polymerase chain reaction (RT-
PCR)/nested PCR in the acute serum sample modified from the
Lanciotti procedure, or virus isolation in the acute serum sample
as described previously [14]. In Ratchaburi, infections were
confirmed by the detection of dengue-specific IgM/IgG antibody
using in-house EIAs or of DENV using virus isolation or RT-PCR
with Lianciotti primers [16]. Both study protocols were reviewed
and approved by the ethics committee of the Thai Ministry of
Public Health (MoPH). In addition, the Ratchaburi protocol was
approved by the Institutional Review Board of IVI, and the
Kamphaeng Phet protocol was approved by the ethical review
committees of the U.S. Army Surgeon General, University of
California at Davis, University of Massachusetts Medical School,
and San Diego State University.
The cohort study in Kampong Cham, Cambodia
A prospective community-based active surveillance study was
performed in 16 rural villages of Kampong Cham Province,
Cambodia, between May to November 2006. Included were
approximately 9,000 children aged 0–15 years. Additional details
of this cohort study have been published previously [17]. In 2007,
the study was carried out between June and December and was
expanded to around 10,000 children aged 0–19 years from 20
rural and 5 urban villages. The sample size calculation based on
expected dengue incidence in the target population and took a
cluster design effect of 2 into account due to the expanded
catchment area and the inclusion of urban and rural areas.
Villages under surveillance were located in 3 districts of Kampong
Cham Province (total population 1.7 million), which is located
approximately 170 km northeast of Phnom Penh (Figure 1). For
the study, a convenience sample of villages from two rural districts
located within an approximately 60 km radius of the capital town
and the capital town’s urban areas was selected. Selected urban
areas’ population density was estimated at ,1,900/km
2 versus
,450/km
2 within rural villages (with the geographic area limited
to the villages and not –in contrast to the above presented data
from Thailand– including the geographic area of the entire
administrative district, making the population density estimates
higher for Cambodian villages). After obtaining consent for
participation from village chiefs and their elders’ council, a field
team visited on a weekly basis all households under fever
surveillance and took temperature of any sick child enrolled in
the study. In 2007, digital thermometers and temperature
logbooks were additionally provided to participating households
to record any suspected fever occurring between two visits. From
children with fever (i.e. $38uC, acute or in the previous 7 days) for
$2 days (in 2006) or 1 day (in 2007), acute and convalescent phase
serum samples were collected by an investigation team after
obtaining signed parental consent. All acute and convalescent
serum specimens were tested for anti-DENV IgM using an in-
house capture EIA (MAC-ELISA). RT-PCR testing was per-
formed only on acute phase specimens that were anti-DENV IgM-
negative and where the convalescent sample was IgM-positive in
order to conserve reagents, followed by cell culture for isolation
when appropriate. RT-PCR was performed using a modified
Lanciotti procedure as described earlier [18,19]. Dengue viruses
were isolated after inoculation of the sera into C6/36 (Aedes
albopictus) and VERO E6 cells cultures followed by virus serotype
identification by direct fluorescent antibody assay using monoclo-
nal antibodies. Since both DENV and Japanese Encephalitis virus
(JEV) are co-circulating in Cambodia and because a serological
cross-reactivity between these two flaviviruses can be observed, all
specimens were systematically tested for anti-DENV and anti-JEV
IgM by an in-house MAC-ELISA as described previously [19].
Symptomatic DENV infection was defined as documented fever
and the detection of either anti-DENV IgM antibodies in the
second serum sample or the detection of DENV in acute serum by
RT-PCR or virus isolation. The study protocol was reviewed and
approved by the Ethical Committee of the MoH Cambodia and
the Institutional Review Board of IVI.
National surveillance data from Thailand and Cambodia
National and provincial level dengue reporting data were
extracted from the national surveillance data base of the MoPH
Thailand and the MoH Cambodia. National data were stratified
by type of management (inpatient vs. outpatient), by year, and by
age-group (0–4, 5–9, and 10–14 years). Provincial level data were
stratified by type of management, by year (Kamphaeng Phet
2004–07, Ratchaburi 2006–07, Kampong Cham 2006–07), and
by age-group (Kamphaeng Phet 5–9 and 10–12; Ratchaburi 0–4,
5–9, 10–14; Kampong Cham 0–4, 5–9, 10–14 years). Total
population data (national and provincial level) were provided by
both ministries stratified by age-group and year.
In Cambodia, the case definitions for reporting of DF and DHF
are adapted from the WHO clinical case definition, but only
hospitalized cases and cases ,15 years of age are reported [17].
The case definitions are based only on clinical and hematological
criteria (according to WHO guideline these are ‘‘suspected’’
dengue cases) and do not require laboratory confirmation. For DF,
the presence of fever with 2 or more of the following signs is
required: Red face or conjunctival injection, headache, retro-
orbital pain, painful muscles or joints, rash, and hemorrhagic
signs. Leucopenia may be present. For DHF, besides the above
listed DF-signs and hepatomegaly or abdominal pain the following
hematological findings are required: Increase in hematocrit $20%
and drop in platelets below 100,000/mm
3.
In Thailand, the adapted WHO clinical case definition is used
to report both hospitalized and non-hospitalized patients of all
ages. Clinical case definitions are available for DF and DHF (as
described for Cambodia) and are supported by hematological
criteria such as leucopenia for DF, or thrombocytopenia and
increase in hematocrit .10–20% from baseline for DHF. Specific
diagnostic tests (e.g. serological tests or RT-PCR) may be ordered
on an individual basis by clinicians and depend on the capacity of
the hospital. Subsequently, dengue cases can be classified as
suspected (i.e. only based on clinical and hematological criteria),
probable (clinical criteria plus supportive serology from a single
blood specimen), and confirmed cases (confirmed by laboratory
criteria). All three case classifications are applied for both DF and
DHF and are used nationwide by all governmental hospitals and
some private clinics and hospitals. A suspected dengue case will be
removed from the surveillance data set, if appropriate laboratory
testing for dengue reveals negative results.
Data analysis
Calculation of multiplication factors. Incidence data from
the field sites were stratified in the same manner as the provincial
reporting data by type of management, year, and age-group. Two
types of multiplication factors were computed. Multiplication
factor 1 (MF1) accounts for underrecognition of inpatient dengue
cases. Age-group specific MF1s were calculated by dividing the
incidence of laboratory-confirmed inpatient dengue cases in the
cohort by the reported incidence of dengue inpatient cases in the
same province and year. Multiplication factor 2 (MF2) gives an
estimate of the true number of outpatient dengue cases. Age-group
Burden of Dengue in Thailand and Cambodia
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laboratory-confirmed dengue outpatients by dengue inpatients in
the cohort by year. In Ratchaburi, blood samples were obtained in
2006 only from clinically-suspected dengue cases and these
patients were routinely hospitalized at the Provincial Hospital.
We therefore only calculated MF2 in Ratchaburi for 2007 when
all febrile cases were tested for dengue.
Estimates for the true number of symptomatic dengue
cases nationally. To estimate the true number of dengue
inpatients in the entire country, the reported national number of
dengue inpatients was multiplied by the average MF1 for each
age-group (0–4, 5–9, and 10–14 years) (Figure 2). For Kamphaeng
Phet, the age-group 10–12 MF1 was assumed to be similar to an
age-group 10–14 MF1. For Ratchaburi, the age-group 3–4
multiplication factors were assumed to be similar to age-group
0–4 multiplication factors. To estimate the true number of
symptomatic outpatient dengue cases in the country, the
estimated true number of dengue inpatients was multiplied with
age-group specific average MF2 (Figure 2). Calculations were
performed for each year 2003–07 with the same average age-
group specific MF1 and MF2.
Results
Thailand
In Thailand, a cumulative total of 14,627 student-seasons
(Kamphaeng Phet) or student-years (Ratchaburi) were studied in
the two cohorts: 8,246 in Kamphaeng Pet 2004–07 and 6,381 in
Ratchaburi 2006–07 (Table 1). The incidence of laboratory-
confirmed symptomatic DENV infection (both inpatients and
outpatients) ranged in both field sites between 13 and 33/1,000
with an average of 23/1,000 in Kamphaeng Phet and 25/1,000 in
Ratchaburi. The average age-group specific incidence per cohort
study is shown in Figure 3. The proportion of cohort subjects
which were lost to follow-up, was in Kamphaeng Phet 2% to 2.5%
(over the 6 month seasonal surveillance period) and in Ratchaburi
approximately 11% (over the entire year in 2006).
In Kamphaeng Phet and Ratchaburi, the incidence of dengue
leading to hospitalization was 4.9/1,000 and 14.7/1,000 and the
average outpatient-inpatient ratios were 3.7:1 and 1:1, respective-
ly. Age-group specific incidence cohort data by year are
summarized in Table 1. The average reported provincial
incidence of dengue inpatient cases over the study periods was
2.6/1,000 in Kamphaeng Phet and 4.5/1,000 in Ratchaburi.
Applying average MFs to age-group specific nationally reported
dengue cases 2003–07 showed an average of 8.7-fold (SD 0.13)
underrecognition of total symptomatic dengue cases in Thailand
each year. The underrecognition of inpatient dengue cases was
estimated to be 2.6-fold (SD 0.02) during this time period. The
calculations suggest that in 2003–07 a median of actually 229,886
(range 210,612–331,236) symptomatic DENV infections occurred
each year in Thailand in the age-group ,15 years with up to
95,527 hospitalizations in 2007.
Average age-group specific MFs and the single steps in the
calculation exemplified by using median numbers of reported
dengue cases in 2003–07 are shown in Table 2. Since these
Figure 2. Methodology used to establish better disease burden estimates of symptomatic dengue virus infections. The estimates are
based on numbers of nationally reported inpatient dengue cases and average multiplication factors (MF), which were generated by comparing
provincial reporting data with data from prospective cohort studies in the same province.
doi:10.1371/journal.pntd.0000996.g002
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cases, the multiplication factors presented in the table (for total
cases 8.37 and for inpatient cases 2.94) varied slightly from the
more precise calculations presented above, which were conducted
for each individual year 2003–07.
Cambodia
In Cambodia, cohort data from 2006 and 2007 were included
in the analysis and were derived from a cumulative 14,493 person-
season under active surveillance. The proportion of children with
refusals or loss to follow-up during the study period was 1.3% in
2006 and 1.7% in 2007. The incidence of laboratory-confirmed
dengue in 2006 and 2007 among children ,15 years of age was
13/1,000 and 64/1,000, respectively. Average age-group specific
incidence is shown in Figure 3, and age-group specific cohort and
reported provincial incidence of dengue leading to hospitalization
is shown by year in Table 1. The outpatient-inpatient ratio was
1.2:1 in 2006 and 8.6:1 in 2007.
Applying average MFs to age-group specific nationally reported
dengue cases in each individual year 2003–07 suggest an average
9.1-fold(SD0.16) underestimation of total number and 1.4-fold(SD
0.02) underestimation of inpatient dengue cases in Cambodia in
2003–07. These estimates suggest that in 2003–07 a median of
111,178 (range 80,452–357,135) symptomatic dengue virus infec-
tions occurred in Cambodia each year with a maximum 58,118
hospitalizations in 2007. Average age-group specific MFs and their
applicationtoexpandnationallyreported data(exemplifiedbyusing
the median number of dengue case 2003–07) are shown in Table 3.
Since these calculations were based on median numbers of reported
dengue cases, the multiplication factors presented in the table (for
total cases 9.27 and for inpatient cases 1.4) varied slightly from the
more precise calculations presented above, which were conducted
for each individual year 2003–07.
Discussion
Best data on disease incidence are usually derived from
prospective community-based cohort studies that actively follow
cohort-participants and use laboratory testing to confirm the
diagnosis. Comparing cohort with national surveillance data can
give an estimate for the underrecognition of the disease in the
country. However, variation in environmental and socioeconomic
conditions can occur in a country causing local differences in
disease transmission and incidence [14]. Therefore, we established
average age-group specific MFs by comparing cohort data with
reporting data on the provincial level. By doing this, we estimated
the magnitude of underrecognition of disease incidence in the
national reporting system of the province, which should not be
severely influenced by the exact level of disease incidence.
However, factors potentially having an impact on the degree of
underrecognition include socio-economic characteristics of the
Table 1. Age-group specific dengue incidence in three cohort studies and reported provincial incidence by year.
Province,
country Year Age-group
Cohort
subjects
(n)
Total
incidence in
the cohort
(per 1,000)
Cohort
outpatient
incidence
(per 1,000)
Cohort
inpatient
incidence
(per 1,000)
Reported province
inpatient incidence
(per 1,000)
MF1 (ratio cohort
inpatient incidence:
reported province
inpatient incidence)
MF2 (ratio
outpatients:
inpatients in
the cohort)
Kamphaeng 2004 5–9 1,383 19.5 15.9 3.6 2.0 1.8 4.4
Phet, 10–12 87 8.7 7.3 1.5 2.0 0.7 5.0
Thailand 2005 5–9 1,317 7.6 6.8 0.8 2.4 0.3 9.0
10–12 755 22.5 17.2 5.3 1.3 4.0 3.3
2006 5–9 1,254 43.1 34.3 8.8 3.4 2.6 3.9
10–12 820 43.9 29.3 14.6 2.4 6.0 2.0
2007 5–9 1,165 18.9 15.5 3.4 2.7 1.3 4.5
10–12 865 17.3 15.0 2.3 4.3 0.5 6.5
Total 5–12 8,246 22.7 17.8 4.9 2.6 1.9 3.7
Ratchaburi, 2006 0–4 265 3.8 0.0 3.8 1.5 2.5 NA*
Thailand 5–9 2,407 17.9 4.6 13.3 6.7 2.0 NA*
10–14 355 19.7 2.8 16.9 4.5 3.8 NA*
2007 0–4 335 44.8 23.9 20.9 2.0 10.3 1.1
5–9 2,126 29.6 13.6 16.0 5.1 3.1 0.9
10–14 893 37.0 21.3 15.7 6.4 2.4 1.4
Total 0–14 6,381 25.4 10.7 14.7 4.5 3.3 1.0
Kampong 2006 0–4 1,685 18.4 9.5 8.9 4.1 2.2 1.1
Cham, 5–9 2,099 16.2 6.2 10.0 4.5 2.2 0.6
Cambodia 10–14 2,910 8.2 6.5 1.7 1.4 1.3 3.8
2007 0–4 2,316 71.2 62.2 9.1 9.4 1.0 6.9
5–9 2,834 76.2 66.7 9.5 10.3 0.9 7.0
10–14 2,649 44.5 43.0 1.5 4.0 0.4 28.5
Total 0–14 14,493 40.6 34.2 6.4 4.6 1.4 5.3
NA, not available.
*In 2006, only clinically dengue-suspected febrile cases that were hospitalized were tested for dengue virus infection in Ratchaburi.
doi:10.1371/journal.pntd.0000996.t001
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urban and rural areas in the country. In Thailand, the cohort
studies included children from both rural and urban areas. Both
studies were conducted in populations of the capital districts with
probably better access to hospitals and higher socio-economic
status than in more remote areas, but on average the population in
these districts does have a lower socio-economic status than for
example the population of the Bangkok metropolitan area (in
2000, around 77% of the employed population of Kamphaeng
Phet and 43% of Ratchaburi province worked in the agricultural
sector) [13]. In Cambodia, areas with rural and urban character-
istics of one large province were included, which may be
representative of rural Cambodia, where 84% of the total
population lives, but not be representative of the entire country.
The major finding of our analysis was that dengue incidence
was underrecognized by more than 8-times in Thailand and more
Table 2. Median reported dengue cases and application of age-group specific multiplication factors (MF), Thailand 2003–2007.
(a) (b) (c) (d) (e) (f) (g)
Age-group
Total
nationally
reported
cases
Total
nationally
reported
inpatient
Average
MF1
Estimated
actual number
of inpatients
(b x c)
Average
MF2
Estimated actual
number of
outpatients (d x e)
Estimated actual
number of total
cases (d+f)
Multiplication
factor tota
cases (g/a)
Multiplication
factor
inpatient
cases (d/b)
0–4 3,120 2,699 6.40 17,274 1.14 19,692 36,966 11.85 6.40
5–9 10,257 9,859 2.03 20,014 3.15 63,043 83,057 8.10 2.03
10–14 14,309 10,044 2.95 29,630 2.77 82,075 111,704 7.81 2.95
Total 27,686 22,602 66,917 164,810 231,727 8.37 2.94
doi:10.1371/journal.pntd.0000996.t002
Figure 3. Dengue age-group specific incidence data in Thailand and Cambodia. Differences are shown between mean reported provincial
incidence and mean cohort incidence of symptomatic dengue virus infections (inpatients and outpatients) by age-group under surveillance in three
field sites: A) Ratchaburi, Thailand, 2006–07; B) Kamphaeng Phet, Thailand, 2004–07; C) Kampong Cham, Cambodia, 2006–07.
doi:10.1371/journal.pntd.0000996.g003
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surveillance systems in Thailand and Cambodia were efficient in
capturing inpatient dengue case with only 2.6-fold and 1.4-fold
underdetection, respectively. However, the surveillance system in
Thailand largely underrecognizes the burden of dengue outpa-
tients and the system in Cambodia does not allow reporting of
outpatients at all. According to our estimates (Table 2 and 3), in
both countries symptomatic dengue outpatients account for more
than 70% of the overall dengue disease burden. It is important to
highlight that national reporting systems are usually designed to
detect outbreaks and to monitor disease incidence trends, but do
not attempt to capture all symptomatic dengue infections in the
country for obvious reasons. Therefore, country-specific multipli-
cation factors derived from studies like ours or from capture-
recapture studies are useful for application to national reporting
data to assess true disease burden and to be used for economic
assessments.
Estimating the underreporting of dengue inpatients on the
provincial level (MF1) and the ratio of outpatients to inpatients
(MF2) showed considerable variation between years and age-
groups both within and between field sites. Possible reasons for
these variations include health structure differences (in Ratchaburi
most cases presented directly at the Provincial Hospital where all
clinically-suspected dengue cases were hospitalized; while in
Kamphaeng Phet only more severe cases were referred from the
public health centers to the hospital), differences in socio-economic
characteristics of the populations, and annual differences in
dengue activity (e.g. the large 2007 dengue-epidemic in Kampong
Cham led to overwhelmed hospitals, thus increasing the
proportion of non-hospitalized dengue cases but also leading to
an overestimation of dengue among hospitalized febrile patients).
However, these differences probably reflect reality and average
age-group specific MFs were comparable between the three field
sites. The inclusion of several field sites and field sites with different
study areas (rural and urban) accounted for some local variation in
economic characteristics of the study population and health care
structure (which might also lead to differences in the proportion of
suspected dengue cases being hospitalized) and is a major strength
of our assessment. Still, the included study areas might not be
representative for the entire country, but should represent large
parts of each country.
For Kamphaeng Phet, the multiplication factor for age-group
10–12 was assumed to be similar to that of age-group 10–14. Since
multiplication factors assess the degree of underrecognition of the
disease, we assumed that there is not a relevant difference in health
seeking behavior or in the hospitalization rate when comparing
children 10–12 with children 13–14 years of age. However, there
might be significant differences in health seeking behavior for the
age-group 0–4 years vs. 5–9 years. Therefore we used for Thailand
only data from the Ratchaburi cohort to assess multiplication
factors for the age-group 0–4 years, and did not expand
multiplication factors from children older than 4 years of age that
were derived in the Kamphaeng Phet study to the 0–4 year age-
group not studied at that site.
For several reasons we believe that the figures we present still
underestimate the true dengue disease burden. First, in Kam-
phaeng Phet and Kampong Cham the cohort studies were only
conducted during the dengue season. The full-year cohort study in
Ratchaburi and the provincial reporting data demonstrated that
there is still some dengue transmission outside the season (data not
shown). On a national level, between 25% and 30% of annually
reported dengue cases were notified in 2006 and 2007 outside the
typical dengue season (typical season: June to November) [20].
Second, in Ratchaburi and Kampong Cham the inclusion criteria
were changed in 2007 accounting also for dengue in patients with
undifferentiated fever. Thus, mild but symptomatic dengue cases
were probably missed in 2006. Third, it can be assumed that the
presence of active surveillance studies in the provinces led to
higher awareness in hospitals and thus better compliance with
dengue case reporting to the national reporting system. Fourth, for
the incidence calculation we used as a denominator the number of
children under surveillance in the beginning of the year or season
and did not account for drop-outs. And finally, only cases aged 0–
14 years were included in the calculation since older age-groups
were not studied in the field sites, and for Cambodia older age-
groups are not reported in the national surveillance system. In
Thailand, between 15,000 and 27,800 cases in individuals older
than 14 years were annually reported between 2003 and 2007 to
the national surveillance system (data not shown) indicating a high
disease burden also in older age-groups. On the other hand, some
overestimation might have occurred in Cambodia since only two
years were studied with a large outbreak occurring in one. Despite
these limitations and considerations we believe that with this
present study we were able to roughly assess the magnitude of
dengue underestimation in Thailand and Cambodia. Interestingly,
our numbers were in the same range as the mainly ‘‘expert-
opinion based’’ multiplication factors (10 for cases 0–15 years)
used in a dengue economic study in Puerto Rico [7].
In this study we did not attempt to distinguish between DF and
DHF-cases. By focusing on the hospitalization status we address the
issue of disease burden rather than pathophysiology [21]. Especially
for economic studies the distinction between hospitalized and non-
hospitalized patients is more important because costs of hospitalized
DF-cases are more similar to hospitalized DHF-cases [10].
Table 3. Median reported dengue cases and application of age-group specific multiplication factors (MF), Cambodia 2003–2007.
(a) (b) (c) (d) (e) (f) (g)
Age-
group
Total
nationally
reported
cases*
Total
nationally
reported
inpatients
Average
MF1
Estimated actual
number of
inpatients
(b x c)
Average
MF2
Estimated actual
number of
outpatients
(d x e)
Estimated
actual number
of total cases
(d+f)
Multiplication
factor total
cases (g/a)
Multiplication
factor inpatient
cases (d/b)
0–4 4,044 4,044 1.60 6,470 3.96 25,623 32,093 7.94 1.60
5–9 5,170 5,170 1.55 8,014 3.81 30,531 38,545 7.46 1.55
10–14 2,781 2,781 0.85 2,364 16.15 38,176 40,540 14.58 0.85
Total 11,995 11,995 16,848 94,330 111,178 9.27 1.40
*In Cambodia only hospitalized dengue cases are reported to the national surveillance system.
doi:10.1371/journal.pntd.0000996.t003
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infection in children ,15 years was comparable between the three
field sites and on average above 20/1,000. This highlights the high
burden dengue poses to this age-group in Southeast Asia and
shows a similar magnitude of the disease as earlier cohort studies in
the region [10,22–25]. It needs to be stressed that disease burden,
age distribution of cases, or ratios between mild and severe dengue
might be different in other dengue-endemic regions such as in the
Americas. A recently performed comparison of dengue incidence
in a pediatric cohort in Nicaragua with data reported to the
National Epidemiological Surveillance program of the Nicaraguan
Ministry of Health identified an average multiplication factor of
21.3 with an incidence of 3.4 to 17.6 cases per 1,000 children in
the cohort [26]. For the Americas especially, but also in countries
like Thailand, it would be ideal to extend dengue cohort studies
into adulthood to better assess disease burden for the total
population.
An effective dengue vaccine is not yet available, but several
vaccine candidates are currently under development [27,28].
Accurate country-level disease incidence data are therefore
urgently needed to assess the true burden of dengue, to calculate
its economic impact and the cost-effectiveness of a potential
dengue vaccine, and to guide policymakers in making vaccine
introduction decisions. Calculating MFs by comparing prospective
laboratory-based cohort data to locally-gathered reporting data (in
our study provincial-level data) is one approach to account for the
underrecognition in national surveillance and reporting systems.
Capture-recapture studies including outpatients would be useful to
confirm these findings.
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